BioSpace News Archive

Wilmington, Delaware, United States: According to the report, the global glycomics market was valued at US$ 0.9 Bn in 2020 and is projected to expand at a CAGR of 11.2% from 2021 to 2031.

Wilmington, Delaware, United States: Artificial insemination is a technique, in which semen with live sperm is collected and introduced into female reproductive tract at proper time with help of equipment.

Fact.MR – A Market Research and Competitive Intelligence Provider: High adoption of surgical laser systems in cosmetic surgeries, refractive eye surgeries, dental procedures, and general surgeries such as tumour removal, cataract removal, plastic surgery, and many others has led this market to record sales worth US$ 2.94 Bn in the year 2021.

Wilmington, Delaware, United States: A sterilant is a sterilizing agent used by the medical industry to inactivate or destroy various types of microorganisms present in surgical instruments and medical supplies.

Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsychiatric disorders, epilepsy, and pain, today announced that Dr. Alan Kozikowski will no longer serve in the role of Chief Scientific Officer.

Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce the appointment of Dr Tracy Cunningham as Chief Medical officer (CMO) with immediate effect.

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Andrea Paul, J.D., as General Counsel and Corporate Secretary, effective August 1, 2022.

Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) (“Company” or “Kraig Labs”), the biotechnology company focused on the development and commercialization of spider silk, announces that, in collaboration with its joint venture partner, Kings Group, the Company has selected a high-quality garment manufacturer to produce Spydasilk’s TM first apparel line.

Xenikos B.V. today announced enrollment of the first patient in a global pivotal Phase 3 clinical study designed to evaluate T-Guard® versus ruxolitinib for the treatment of patients with Grade III or IV steroid-refractory acute graft-versus-host disease (SR-aGVHD) following allogeneic hematopoietic stem cell transplant (allo-HSCT).

Capricor Therapeutics today announced positive one-year results from its HOPE-2 open label extension study in non-ambulant patients with later-stage Duchenne muscular dystrophy (DMD).